Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Status:
Terminated

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to <4 years of age to help develop dosing regimens

Phase 1

Novartis Pharmaceuticals

Imatinib Mesylate